Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer

Ananaya Datta-Mitra, Navdeep K. Riar, Siba P Raychaudhuri

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.

Original languageEnglish (US)
Pages (from-to)632
Number of pages1
JournalIndian Journal of Dermatology
Volume59
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

Psoriatic Arthritis
Renal Cell Carcinoma
Psoriasis
Therapeutics
Vascular Endothelial Growth Factor A
Phosphotransferases
Monoclonal Antibodies
Bevacizumab
Neoplasms

Keywords

  • Angiogenesis
  • bevacizumab
  • psoriatic arthritis

ASJC Scopus subject areas

  • Dermatology

Cite this

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. / Datta-Mitra, Ananaya; Riar, Navdeep K.; Raychaudhuri, Siba P.

In: Indian Journal of Dermatology, Vol. 59, No. 6, 01.11.2014, p. 632.

Research output: Contribution to journalArticle

@article{0d24c8bb60e242cdba04078309c3e61d,
title = "Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer",
abstract = "Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.",
keywords = "Angiogenesis, bevacizumab, psoriatic arthritis",
author = "Ananaya Datta-Mitra and Riar, {Navdeep K.} and Raychaudhuri, {Siba P}",
year = "2014",
month = "11",
day = "1",
doi = "10.4103/0019-5154.143574",
language = "English (US)",
volume = "59",
pages = "632",
journal = "Indian Journal of Dermatology",
issn = "0019-5154",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "6",

}

TY - JOUR

T1 - Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer

AU - Datta-Mitra, Ananaya

AU - Riar, Navdeep K.

AU - Raychaudhuri, Siba P

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.

AB - Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.

KW - Angiogenesis

KW - bevacizumab

KW - psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=84908476374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908476374&partnerID=8YFLogxK

U2 - 10.4103/0019-5154.143574

DO - 10.4103/0019-5154.143574

M3 - Article

VL - 59

SP - 632

JO - Indian Journal of Dermatology

JF - Indian Journal of Dermatology

SN - 0019-5154

IS - 6

ER -